Hengrui and WuXi AppTec Make Hurun Global 500 2023 with Valuations Exceeding RMB 100 Billion

Feb 20, 2024 14:41 CST Updated 14:41

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

WuXi AppTec

New Drug R&D and Production Service Provider

Eli Lilly

Global Pharmaceutical R&D and Production Company

Novo Nordisk

Insulin Developer and Manufacturer

Mindray

Medical Device R&D Manufacturer

Scan the QR code below!

Free! Free! Free Registration

Disclaimer: This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to relevant medical and health information, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Reposting of this article requires authorization.

Recently, the Hurun Research Institute released the "2023 Hurun Global 500" (2023 Hurun Global 500), listing the world's 500 strongest non-state-owned enterprises, ranked according to market value or valuation (the market value of listed companies is calculated based on the closing price as of October 31, 2023, and the valuation of non-listed companies is estimated by referencing comparable listed companies in the same industry or based on the latest round of financing).

According to statistics,A total of 48 healthcare companies were selected for this list.。

Eli Lilly ranked ninth on the list with a corporate valuation of 380.8 billion yuan.。

Novo Nordisk ranked 14th with a corporate valuation of 3,135 billion RMB.

This year's Top 500 list includes three Chinese healthcare companies., respectively:Mindray Bio-Medical、Hengrui Pharma、WuXi AppTec。

Among them,Hengrui Pharma ranked 366th with a corporate valuation of 304 billion RMB., rising 47 places compared to last year.

WuXi AppTec ranked 418th with a corporate valuation of 261 billion yuan.

The complete list of "2023 Hurun Global 500" is as follows:

The following activities are unrelated to the above content.

Scan the QR code below!

Free! Free! Free Registration

March 1st - Venue 1

MAH Policy and Regulatory Session

09:00-09:30

Analysis of Industry Trends and Corporate Transformation under the MAH System B Certificate
Zhang ZiranDistinguished Vice President of the China Chemical Pharmaceutical Industry Association

09:30-10:00

MAH Contract Manufacturing - Latest Regulatory Policy Interpretation
Jiang RongAssociate Professor at China Pharmaceutical University

10:00-10:30

Project Roadshow
New and Old Drug Approvals / High-Quality Project Resource Connection

10:30-10:50

Tea Break

10:50-11:20

How Can MAH Fully Implement the Main Responsibility in the Management of Drug Contract Manufacturing Under the New Situation?
MAH Industry Expert

11:20-12:00

Key Points and Common Defect Analysis for MAH On-site Inspection

Teacher RenNational GMP Inspector for Pharmaceuticals

MAH Product Launch and Project Collaboration Session

14:00-14:30

Project Initiation Ideas for MAH Generic Drugs Under the Centralized Procurement Situation
Zhang TingjieFounder of Fengyun Pharma Talk

14:30-15:00

How Can Marketing Authorization Holders Transfer Approval Under the MAH System in China?

15:00-15:40

Project Roadshow
Project Investment and Financing Matching Session

15:40-16:00

Tea Break

16:00-16:30

Project Management and Decision-Making in Drug Development Under the MAH System

Wang MengFormer CDE Reviewer

16:30-17:00

Practice of Selection and Audit of Entrusted Manufacturing Enterprises under the MAH System

Huang XiaofengHuayi Pharma Quality Authorised Person

March 2 - Venue 1

Year of the Dragon First Gathering · Yangtze River Delta Pharmaceutical Entrepreneurs Resource Matching Conference

09:00-09:30

Collision and Integration of Entrepreneurial Resources (I)

09:30-10:00

Project Roadshow
New and Old Drug Approvals / High-Quality Project Resource Connection

10:00-10:20

Tea Break

10:20-11:50

Collision and Integration of Entrepreneurial Resources (Part II)

MAH & CXO Practical Session

14:00-14:40

Under Strict Regulation, How B-License Enterprises Strengthen the Construction of Quality Management Systems
Hua Rong BuMAH Expert, General Manager of WuXi AppTec

14:40-15:20

Product Technology Transfer Regulatory Requirements and Practical Guidelines
Ma JianFormer Reviewer of Zhejiang Provincial Center for Drug and Cosmetic Evaluation

15:20-15:50

Management of Post-Marketing Changes and Case Sharing

Cao XuechunHuayi Taikang Pharmaceutical Registration Director

15:50-16:30

Risk Assessment of Multi-Product Contract Manufacturing by CDMOs under the MAH System

Zhou PengchengNational GMP Inspector for Pharmaceuticals

March 1 - Venue Two

Drug Delivery Technology Session

09:00-09:30

Topic Selection and Clinical Considerations for Complex Injectable Formulations
He ZhongguiChief Scientist of Shenyang Xinda Taikang Pharmaceutical Technology Co., Ltd.

09:30-10:00

Chemical Imaging Applied in Formulation Polymorph Analysis and Prescription Process Development

Xie ZhipingSenior Researcher at Fuzhou Huawei Pharmaceutical Technology Development Co., Ltd.

10:00-10:30

Application of Flow-Through Cell Dissolution Apparatus in the Dissolution of Complex Injectable Formulations

Duan YunjianTechnical Director of Shenzhen Huarong Analysis Instrument Co., Ltd.

10:30-10:50

Tea Break

10:50-11:20

Innovative Drug Development: Nasal Delivery Strategies

Zhou JianpingProfessor at China Pharmaceutical University

14:30-15:00

Oral Film Preparations: Advantages, Challenges, and Limitations of the Novel Drug Delivery Technology
Chen FangResearcher at the National Engineering Research Center for Advanced Pharmaceutical Manufacturing

11:50-14:00

Lunch

14:00-14:30

Current Status of Nanoparticle Formulations and Exploration of Novel Nanotechnology Applications

Yao JingProfessor at China Pharmaceutical University

14:30-15:00

Key Considerations for Excipient Selection and Quality Control in Complex Injectable Formulations
Sun ChunmengProfessor at China Pharmaceutical University

15:00-15:40

Project Roadshow
New and Old Drug Approvals / High-Quality Project Resource Connection

15:40-16:00

Tea Break

16:00-16:30

Application and Challenges of Dissolving Microneedle Technology in the Pharmaceutical Field

Li ChengguoCo-founder of Youwei (Zhuhai) Biotechnology Co., Ltd.

16:30-17:00

Development Challenges and Industrialization Barriers of Improved Inhalation Formulations
Tong ZhenboProfessor at Southeast University

March 2 - Venue Two

Transdermal Preparations Session

09:00-09:30

Microneedle Drug Controlled Release System: Innovation and Translation
Gu ZhenProfessor at Zhejiang University

09:30-10:00

Comparison of Domestic and International Regulations for the Development of Topical Dermatological Products and Case Analysis
Zhang XingyiFormer CDE Reviewer

10:00-10:20

Tea Break

10:20-10:50

Different Designs and Strategic Considerations in the Development of Modified and Generic Transdermal Patch Products
Quan DanyiDirector of Jiangsu Jicui New Drug Formulation Technology Research Institute

10:50-11:20

Current Status and Prospects of Excipients in Transdermal Absorption Preparations

Wu ZhenghongProfessor at China Pharmaceutical University

11:20-11:50

Quality Research Strategies for Topical Dermatological Formulations

Zhang JingDirector of R&D, Suzhou Gaomai Pharmaceuticals Co., Ltd.

Generic Drugs / Improved New Drug Project Launch Session

14:00-14:40

How to Initiate the Improvement of New Drugs from Clinical Value?
Wei ShifengChairman and CEO of Beijing Ronnoqiangshi Pharmaceutical Technology Research and Development Center Co., Ltd.

14:40-15:20

Topic Selection and Project Initiation Strategies for High-End Generic Drugs and Improved New Drugs

15:20-16:00

Strategic Layout and Product Line Planning for Generic Drug Companies in the New Situation

Guo XinfengFounder of Nanjing Evidence-Based Biotechnology Co., Ltd.